You are not alone because we are there for you

A patient’s response to a drug is often linked to common genetic variations present in their genes. Knowing the types of genetic variations present in a patient can help predict the associated drug response. This not only helps to individualize drug therapy, but also improve effectiveness of the drug, decrease the chance of negative side effects and save healthcare costs. Accurate prediction about drug response is crucial for individualized treatment. This is best made by combining an individual’s genetic data with clinical findings

The pharmacogenetic studies the influence of genetic activity of a drug, its assimilation and its metabolism. The aim of pharmacogenetics is to use the genetic information in the selection of the drug to maximize effectiveness and minimize its side effects and unintended response.

Neuropharmagen helps you to:

  1. Analyze drug response
  2. Define dosage at an individual level
  3. Reduce the appearance of adverse side effects

neur

                                         (Click on the image to magnify)

PROCEDURE
  • Neuropharmagen test is typically performed on a sample of saliva. The kit includes all the material and documents to collect the sample and order the test
  • The test is designed for use by doctors: the Neuropharmagen test report contains specialized information that requires the interpretation of a medical professional. Therefore any test request must be signed by a physician.
  • Results are available online within 10 working days.
CONSIDERATIONS TO TAKE INTO ACCOUNT
  • DO NOT eat or drink, smoke, or chew gum 30 minutes before you get your saliva sample. DO NOT remove the plastic film from the top of the funnel.
  • It is recommended to help with the tongue to rub the inner walls of the gums and cheeks.
  • Should be difficult to obtain the sample taken a few grains of white sugar, placing them under the tongue (promotes saliva production without interfering in the subsequent extraction of DNA).
  • If you have any questions we are available through info@ilifediscoveries.com  

YOU CAN ALSO CONTACT US CLICKING THE CONTACT US BUTTON BELOW

Neuropharmagen® is a genetic test developed by AB-BIOTICS SA, a biotechnology company founded in 2004 as a spin-off of the Autonomous University of Barcelona. The company maintains a close relationship with the Faculty of Medicine of the Autonomous University of Barcelona and the University of Girona. iLife Discoveries is the exclusive technology partner to AB Biotics in India.
To perform a genetic test requires a sample of the patient’s DNA. The test is performed through a simple analysis patient’s saliva.
Our group of experts in genetics and molecular biology has found that there is no difference between the results obtained with the saliva test than the blood test.
The workshop recommended the use of saliva rather than blood for three reasons:
1.Ability to obtain a sample in situ, without the need for a nurse/phlebotomist, so an non-invasive procedure ensures fast and comfortable process for the patient.
2.The sample can be stored at room temperature (the blood must instead be stored at 4 ° C) until our logistic partner picks it up and couriers it to us;
3.The DNA in the saliva remains stable for 4 weeks (compared to a maximum of 48 h for the blood sample).
Neuropharmagen® is based on the findings of numerous scientific studies conducted over the last decade, which have shown that genetics has a significant impact on each individual’s response to drugs. We are all different from the genetic point of view and these differences mean that each of us responds differently to medications.
Neuropharmagen® is a genetic test used in neurology and psychiatry that, from the patient’s DNA, helps identify the drug most suitable for each individual, thus reducing the time between diagnosis and effective treatment, and helping to identify the right treatment from the outset. The test results allow the physician to: 1. Identify the most suitable drug for the patient; 2. Adjust the dose at the individual level from the start of treatment; 3. Avoid making excessive changes to the treatment; 4. Reduce risk of side effects.
Neuropharmagen® is not a diagnostic test, nor analyzes the causes of the disease. Neuropharmagen® analyzes, through a DNA test, the probability of response to a set of drugs, and then provides the physician a series of information that will help him to choose the most suitable drug and dosage for the patient.
The test is only relevant for drugs that currently have proven pharmacogenetic information, validated through trials and recommended by international guidelines. After reviewing the information published so far, scientists have pooled in the evidences and formulated an algorithm which works on the genotypic data. The list is not exhaustive, more drugs would be a part of this panel, as and when their pharmacogenetic markers are well established.
The test is a high throughput test wherein the sample is evaluated genetically for responses for a range of drugs. It involves genotyping, sequencing and then analyzed for pharmacogenetic implications. It cannot be done for a smaller panel.
For now, the FDA provides only non-binding recommendations. The FDA publishes on its website a list of drugs for which pharmacogenetic testing needs to be done before prescribing.
The laboratory ensures confidentiality of the patient and his/her genetic data obtained and compliance with the Law on the protection of data. The whole process of test requisition, reporting and interpretation is routed through the physician ensuring confidentiality. The whole process is bar coded, and labeled as NFGINXXXXX , and the same reflects back on the report.
If the drug is marked with the word “Standard” means that the analyzed genes linked to this drug doesn’t infer any genetic advantage with respect to response or metabolism. The drug then has to be administered in a way representing the average population. However “Green” represents those drugs, in which the particular person holds a genetic advantage, the drug would have a greater likelihood of a positive response. Therefore, In the absence of other information (patient history, concomitant medications, etc.), the drugs reported in GREEN are preferable to those marked as “Standard”.
The drugs mentioned in “RED” have been found to be associated to more likelihood of adverse drug reactions, with respect to the pharmacogenetic implications true to the genotype of the patient. These drugs, if administered, would likely to initiate adverse and unwarranted drug reactions.
There are many more genetic and environmental factors that significantly affect the response to drugs, which influences a drug response, and this is a very dynamic field, but by giving an informed panel of favorable drugs to the physician, he/she can expect quicker and anticipated response from the patient.
The drugs empanelled in this test include those which have been found to have pharmacogenetic markers validated and established. It is on the discretion of the physician to extrapolate findings for drugs whose markers has still not been characterized.
The result report includes an attachment with information on potential drug-drug interactions with concomitant medications related enzymes of cytochrome P450 metabolism. In the tables are collected the data for the drugs of interest, totally or partially metabolized by major P450 enzymes, and whose metabolism can be influenced by concomitant therapy.
In some cases Neuropharmagen® can confirm the presence of genetic factors likely to be responsible for the lack of response and / or poor tolerability of a group of drugs, which may be due, for example, to an alteration of the metabolic status that affects various psychotropic drugs. Neuropharmagen® will also be useful to propose alternatives and examine any genetic information that can assist physicians in their identification and selection.
At a technical level, the test is reliable to 99.9%. In addition, a clinical study was performed on 21 patients, conducted by Dr.. Jerónimo Saiz and Dr. Miguel Vega Hospital Ramón y Cajal (reference center in the field of psychiatry in Madrid), the results showed that:
• L ‘81% of patients were receiving treatment suboptimal or improvable;
• Based on the results of the analysis, was proposed modification of therapy in 57% of cases analyzed.

  • The test Neuropharmagen® is typically performed on a saliva sample; the process of sampling is therefore easy, painless and non- invasive.
  • The kit includes all the material and documents to collect the sample and order the test.
  • The test is designed for use by doctors: the Neuropharmagen test report contains specialized information that requires the interpretation by a medical professional. Therefore any test request must be signed by a physician.
  • Confidentiality is maintained all through the process, the referring physician will be the point of contact.
  • Results are available online within 12 working days.

Recommendations for the patient 30 minutes before sample collection

  • Do not take food
  • Do not drink liquids
  • Do not chew gum (chewing gum)
  • No smoking
  • Remove lipstick

1ml saliva is needed.

In order to increase the production of saliva and the amount of DNA contained in it, it is appropriate to rub the inside of the cheeks with the tongue for 30 seconds.

If collection of the sample of saliva appears problematic, placed under the tongue few grains of white sugar, so as to promote the production of saliva without interfering with the process of extraction of the DNA to follow.

WE WOULD LOVE TO HEAR FROM YOU

Contact us